112 related articles for article (PubMed ID: 35121220)
1. Anti-cancer effects of pyrazole-platinum(II) complexes combined with anti-MUC1 monoclonal antibody versus monotherapy in DLD-1 and HT-29 colon cancer cells.
Supruniuk K; Czarnomysy R; Muszyńska A; Radziejewska I
Transl Oncol; 2022 Apr; 18():101348. PubMed ID: 35121220
[TBL] [Abstract][Full Text] [Related]
2. Combined Action of Anti-MUC1 Monoclonal Antibody and Pyrazole-Platinum(II) Complexes Reveals Higher Effectiveness towards Apoptotic Response in Comparison with Monotherapy in AGS Gastric Cancer Cells.
Supruniuk K; Czarnomysy R; Muszyńska A; Radziejewska I
Pharmaceutics; 2021 Jun; 13(7):. PubMed ID: 34206951
[TBL] [Abstract][Full Text] [Related]
3. The combined treatment with novel platinum(II) complex and anti-MUC1 increases apoptotic response in MDA-MB-231 breast cancer cells.
Gornowicz A; Bielawska A; Czarnomysy R; Gabryel-Porowska H; Muszyńska A; Bielawski K
Mol Cell Biochem; 2015 Oct; 408(1-2):103-13. PubMed ID: 26112902
[TBL] [Abstract][Full Text] [Related]
4. Anti-cancer effect of combined action of anti-MUC1 and rosmarinic acid in AGS gastric cancer cells.
Radziejewska I; Supruniuk K; Bielawska A
Eur J Pharmacol; 2021 Jul; 902():174119. PubMed ID: 33930385
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of anticancer action of novel berenil complex of platinum(II) combined with anti-MUC1 in MCF-7 breast cancer cells.
Gornowicz A; Bielawska A; Szymanowski W; Gabryel-Porowska H; Czarnomysy R; Bielawski K
Oncol Lett; 2018 Feb; 15(2):2340-2348. PubMed ID: 29434943
[TBL] [Abstract][Full Text] [Related]
6. A novel series of pyrazole-platinum(II) complexes as potential anti-cancer agents that induce cell cycle arrest and apoptosis in breast cancer cells.
Czarnomysy R; Surażyński A; Muszynska A; Gornowicz A; Bielawska A; Bielawski K
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1006-1023. PubMed ID: 29862867
[TBL] [Abstract][Full Text] [Related]
7. Tiliroside Combined with Anti-MUC1 Monoclonal Antibody as Promising Anti-Cancer Strategy in AGS Cancer Cells.
Radziejewska I; Supruniuk K; Jakimiuk K; Tomczyk M; Bielawska A; Galicka A
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685842
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic efficacy of a novel dinuclear platinum(II) complex used with anti-MUC1 in human breast cancer cells.
Gornowicz A; Kałuża Z; Bielawska A; Gabryel-Porowska H; Czarnomysy R; Bielawski K
Mol Cell Biochem; 2014 Jul; 392(1-2):161-74. PubMed ID: 24639126
[TBL] [Abstract][Full Text] [Related]
9. A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.
Wu G; Kim D; Kim JN; Park S; Maharjan S; Koh H; Moon K; Lee Y; Kwon HJ
Theranostics; 2018; 8(1):78-91. PubMed ID: 29290794
[No Abstract] [Full Text] [Related]
10. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
Lavrsen K; Madsen CB; Rasch MG; Woetmann A; Ødum N; Mandel U; Clausen H; Pedersen AE; Wandall HH
Glycoconj J; 2013 Apr; 30(3):227-36. PubMed ID: 22878593
[TBL] [Abstract][Full Text] [Related]
11. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer.
Nakamura H; Hinoda Y; Nakagawa N; Makiguchi Y; Itoh F; Endo T; Imai K
J Gastroenterol; 1998 Jun; 33(3):354-61. PubMed ID: 9658314
[TBL] [Abstract][Full Text] [Related]
12. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma.
Burton J; Mishina D; Cardillo T; Lew K; Rubin A; Goldenberg DM; Gold DV
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3065s-3072s. PubMed ID: 10541345
[TBL] [Abstract][Full Text] [Related]
13. A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model.
Wu G; Maharjan S; Kim D; Kim JN; Park BK; Koh H; Moon K; Lee Y; Kwon HJ
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987260
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.
Pegram MD; Borges VF; Ibrahim N; Fuloria J; Shapiro C; Perez S; Wang K; Schaedli Stark F; Courtenay Luck N
Breast Cancer Res; 2009; 11(5):R73. PubMed ID: 19811637
[TBL] [Abstract][Full Text] [Related]
15. Mucin 1 as a Molecular Target of a Novel Diisoquinoline Derivative Combined with Anti-MUC1 Antibody in AGS Gastric Cancer Cells.
Gornowicz A; Szymanowski W; Bielawski K; Kałuża Z; Michalak O; Bielawska A
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770912
[TBL] [Abstract][Full Text] [Related]
16. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library.
Ohyabu N; Hinou H; Matsushita T; Izumi R; Shimizu H; Kawamoto K; Numata Y; Togame H; Takemoto H; Kondo H; Nishimura S
J Am Chem Soc; 2009 Dec; 131(47):17102-9. PubMed ID: 19899793
[TBL] [Abstract][Full Text] [Related]
17. Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells.
Pichinuk E; Benhar I; Jacobi O; Chalik M; Weiss L; Ziv R; Sympson C; Karwa A; Smorodinsky NI; Rubinstein DB; Wreschner DH
Cancer Res; 2012 Jul; 72(13):3324-36. PubMed ID: 22507854
[TBL] [Abstract][Full Text] [Related]
18. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis.
Rabassa ME; Croce MV; Pereyra A; Segal-Eiras A
BMC Cancer; 2006 Oct; 6():253. PubMed ID: 17064405
[TBL] [Abstract][Full Text] [Related]
19. Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro.
Shimizu M; Imai M
Biol Pharm Bull; 2008 Dec; 31(12):2288-93. PubMed ID: 19043215
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of mucin gene expression in normal and neoplastic tissues.
Ho SB; Niehans GA; Lyftogt C; Yan PS; Cherwitz DL; Gum ET; Dahiya R; Kim YS
Cancer Res; 1993 Feb; 53(3):641-51. PubMed ID: 7678777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
